Strategic area of application
Medical Technologies
Application market
Immune, AutoIm & Inflam. diseases - Neurological diseases - Oncology
Activities
Therapeutics, Pharma or Biotech
Technologies
Others
Presentation of company's activity
genOway is fully dedicated to the development of tailor-made transgenic mice, rats and cell lines, and has engineered over 1,600 models, while serving clients in 28 countries worldwide, 265 academic institutions and 13 EU projects, 70 biopharmaceutical, and 14 of the TOP 20 pharma companies.
Based on our success, genOway is proud to offer a variety of quality transgenesis services and a complete range of innovative cutting-edge technology solutions to help add value and substance to your research program. This combination of expertise speeds up model development times and enhances the efficiency, security and relevance of the animal model ultimately developed.
Two Cost- and Time-saving solutions:
1) As a "One-stop" provider, genOways industrialized production facility guarantees the development of projects from A to Z (from the design to model validation/phenotyping)
2) In order to maximize the use of in vivo models, genOway has developed the concept of “2-in-1” models. Target validation (Knock-out), in vivo evaluation of compounds towards the human target (humanized mouse) and compound specificity studies can all be addressed within a single animal model.
Moreover, genOway develops animal models as ready-to-use tools aiming at increasing the predictability of in vivo pre-clinical analysis in many areas such as ADME-tox, Immunology, Neurology and Metabolic disorders. The use of these ready-to-use models enables more relevant analysis of physiopathological studies compare to human physiology and increases the relevance of candidate molecules selection.
Presentation of company's services
In addition to providing highly advanced technological solutions for transgenesis and model design, genOway offers interactive scientific consulting at every step as an essential part of the process. This premium consulting service allows genOway not just to better understand specific research needs and objectives but also to help enhance the reliability of in vivo studies.
genOway guarantees its customer access to a permanent, non-exclusive royalty-free license over patented technologies employed to create rodent or cellular models in order to use such a model for Research and Development purposes. The customer retains the ownership of the deliverables and can patent the model developed.
Presentation of company's technologies
genOway has an unparalleled portfolio of exclusive technologies that enables us to generate biologically relevant models while limiting the drawbacks of typical genetic modifications (e.g. embryonic or perinatal lethality, unregulated over expression of transgenes, genetic deregulation, non relevant physiological responses, etc.).
These technologies are thus able to provide scientists access to more refined genetically modified models.
- Homologous Recombination: Reference technology for humanized, Knockin and conditional Knockout models
- CRISPR/Cas9 Nuclease System: Reference technology for genetically modified rat and cellular models
- FLEx technology: Gold standard for the generation of kinase-dead mutations, inducible in a temporal and tissue-specific manner
- TET On/Off system: “On demand” gene induction
- Quick Knockin: Fast model development by transgene introduction into known permissive loci (e.g. HPRT, Rosa26)
- RMCE: Enables the swapping of large genomic regions, and recommended for the development of humanized models
